Valeant Pharmaceuticals Intl Inc (NYSE:VRX): What to Expect From Earnings?
- Author: Zachary Reyes Mar 01, 2017,
Mar 01, 2017, 3:13
The Market Capitalization of the company stands at 5.58 Billion.
Valeant reported a 13% drop in sales during the fourth quarter, which it attributed to declining sales of existing products.
Shares of Shutterstock, Inc.
Koffler kept her underperform rating and 9 price target on Valeant stock.
Valeant Pharmaceuticals International, Inc.is a pharmaceutical company which engages in developing, manufacturing, and marketing pharmaceutical products in the areas of dermatology, eye health, neurology, and generics. Five investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and six have given a buy rating to the company. These price targets are a consensus analysis of 19 brokers. (NYSE:VRX) is trading up on a volume of 16.84 million, or 1.17 times its standard daily volume. Convector Capital Management LP now owns 192,000 shares of the specialty pharmaceutical company's stock valued at $3,867,000 after buying an additional 67,000 shares during the period.
The company's 50 day moving average is 15.01 and its 200 day moving average is 20.14.
Valeant Pharmaceuticals International (VRX) revealed a profit for fourth quarter that lost ground from previous year.
Valeant Pharmaceuticals International, Inc. on 11/08/2016 reported its EPS as $1.55 with the analysts projecting the EPS of the stock as $1.75.
"We identified what we referred to as $2 billion of revenue for what I would refer to as non-core", he said, adding that those assets could generate up to $8 billion in proceeds if unloaded - though he doesn't expect all to sell - and help pay down the the whopping $29 billion in debt looming over his company.
Valeant has negative profit margins and returns despite having a profitability rank of 7. Excluding certain items, the company earned $1.26 a share, compared with $1.55 the year before.
A number of other equities analysts also recently commented on the company.
"Valeant Pharmaceuticals International's (VRX) "Neutral" Rating Reaffirmed at Rodman & Renshaw" was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was copied illegally and republished in violation of U.S. and worldwide trademark and copyright law. The original version of this news story can be viewed at [[permalink]]. The stock was bought at an average cost of $14.73 per share, with a total value of $73,650.00. Also, Director Thomas W. Sr. Ross purchased 5,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Wednesday, December 14th. The stock was sold at an average price of $14.85, for a total value of $51,628,846.50. The disclosure for this sale can be found here.
Several hedge funds have recently added to or reduced their stakes in VRX. Phoenix Investment Adviser LLC increased its position in Valeant Pharmaceuticals International by 1.2% in the second quarter. Morgan Stanley raised its stake in Valeant Pharmaceuticals International by 241.6% in the third quarter.
EPS growth in next year is estimated to reach -10.37% while EPS growth estimate for this year is set at -133.00%.
The Company now has Insider ownership of 2.3 Percent and Institutional Ownership of 66.8 Percent.